BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
about
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatmentBRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer.The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.Therapeutic targeting and patient selection for cancers with homologous recombination defects.The integration of BRCA testing into oncology clinicsOlaparib and somatic BRCA mutations.Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma.Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.BRCA1/2 testing: therapeutic implications for breast cancer managementHomologous recombination deficiency in ovarian cancer: a review of its epidemiology and managementOne-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer
P2860
Q28075761-A5A04CCB-F117-4EAF-9C54-8F7C8A6E27DBQ33750060-10BB503E-57FD-429F-A7C1-CE211D80987BQ36369910-F1EF6AAC-7E71-4AB4-B955-00926A12C9CBQ37661436-808380D6-2B5E-4644-A27F-A225881FACABQ38645200-D5F0183D-8136-4358-B691-68B1CD2AF9E8Q38734927-13ADBE42-AE0F-4438-A8D7-C68B23C22A1CQ38975570-A0473325-8F44-4AB2-8E9A-BE9E2201EB81Q39251572-D43BC6A0-B90E-4A12-B402-EE7637DFD0C8Q40681608-C700F190-A6F2-46D7-BFE4-B13A669B05BDQ42343103-8C83295E-4C7D-45E3-8BA4-D1B350596B7EQ48110433-2BFACE48-85D8-4C51-B1B5-705E8522B44BQ48227450-41484A48-79E6-49FC-9CF0-F9C6C67D2B4AQ49909339-8F056071-B926-4653-BB1B-381DA2D4232FQ52714606-D7EE1F08-9B04-42EC-92E7-8E28ED083BAAQ55041688-1E66689A-D38F-46D2-AE09-B8C66B44EC6BQ55121518-656DF609-D465-4437-97DD-A5EA2EF78285Q55416207-AA779D33-ADC3-4343-86F8-FF7FF742F886Q57110101-7152BDEE-761F-4F97-9914-1BC1CADD0824Q58801181-1AA28FBD-BD81-4EE9-81E2-278EE8F53DD9Q59134002-D63778C8-F311-4D45-9B12-3BE208D8E5C9
P2860
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
@en
type
label
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
@en
prefLabel
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
@en
P2093
P2860
P356
P1433
P1476
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDW142
P577
2016-03-31T00:00:00Z